286 related articles for article (PubMed ID: 16702617)
41. No association between cytochrome P450 2D6 gene polymorphism and risk of acute leukemia: evidence based on a meta-analysis.
Ruan XL; Li S; Zeng XT; Xia LH; Hu Y
Chin Med J (Engl); 2013; 126(19):3750-3. PubMed ID: 24112176
[TBL] [Abstract][Full Text] [Related]
42. Familial incidence of dystonic reactions to metoclopramide (maxolon).
Gatrad AR; Gatrad AH
Br J Clin Pract; 1979 Apr; 33(4):111, 115. PubMed ID: 475953
[No Abstract] [Full Text] [Related]
43. Metoclopramide induced acute dystonic reaction: a case report.
Tianyi FL; Agbor VN; Njim T
BMC Res Notes; 2017 Jan; 10(1):32. PubMed ID: 28061898
[TBL] [Abstract][Full Text] [Related]
44. Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6.
Niwa T; Hiroi T; Tsuzuki D; Yamamoto S; Narimatsu S; Fukuda T; Azuma J; Funae Y
Brain Res Mol Brain Res; 2004 Oct; 129(1-2):117-23. PubMed ID: 15469888
[TBL] [Abstract][Full Text] [Related]
45. The impact of CYP2D6 genetic polymorphisms on postoperative morphine consumption.
Candiotti KA; Yang Z; Rodriguez Y; Crescimone A; Sanchez GC; Takacs P; Medina C; Zhang Y; Liu H; Gitlin MC
Pain Med; 2009; 10(5):799-805. PubMed ID: 19523031
[TBL] [Abstract][Full Text] [Related]
46. Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia.
Yagihashi T; Mizuno M; Chino B; Sato Y; Sakuma K; Takebayashi T; Takao T; Kosaki K
Hum Psychopharmacol; 2009 Jun; 24(4):301-8. PubMed ID: 19387994
[TBL] [Abstract][Full Text] [Related]
47. CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited.
Ozdemir V; Bertilsson L; Miura J; Carpenter E; Reist C; Harper P; Widén J; Svensson JO; Albers LJ; Kennedy JL; Endrenyi L; Kalow W
Pharmacogenet Genomics; 2007 May; 17(5):339-47. PubMed ID: 17429316
[TBL] [Abstract][Full Text] [Related]
48. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study.
Kobylecki CJ; Jakobsen KD; Hansen T; Jakobsen IV; Rasmussen HB; Werge T
Neuropsychobiology; 2009; 59(4):222-6. PubMed ID: 19521114
[TBL] [Abstract][Full Text] [Related]
49. Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study.
Mulder H; Heerdink ER; van Iersel EE; Wilmink FW; Egberts AC
Ann Pharmacother; 2007 Mar; 41(3):408-13. PubMed ID: 17341534
[TBL] [Abstract][Full Text] [Related]
50. Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57).
Sakuyama K; Sasaki T; Ujiie S; Obata K; Mizugaki M; Ishikawa M; Hiratsuka M
Drug Metab Dispos; 2008 Dec; 36(12):2460-7. PubMed ID: 18784265
[TBL] [Abstract][Full Text] [Related]
51. Acute dystonic reaction caused by metoclopramide, versus tetanus.
Dingli K; Morgan R; Leen C
BMJ; 2007 Apr; 334(7599):899-900. PubMed ID: 17463462
[TBL] [Abstract][Full Text] [Related]
52. A case of metoclopramide-induced oculogyric crisis in a 16-year-old girl with cystic fibrosis.
Lou E; Abou-Zeid N
South Med J; 2006 Nov; 99(11):1290-1. PubMed ID: 17195428
[TBL] [Abstract][Full Text] [Related]
53. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI
J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106
[TBL] [Abstract][Full Text] [Related]
54. Allelic distributions of CYP2D6 gene copy number variation in the Eastern Han Chinese population.
Sheng HH; Zeng AP; Zhu WX; Zhu RF; Li HM; Zhu ZD; Qin Y; Jin W; Liu Y; Du YL; Sun J; Xiao HS
Acta Pharmacol Sin; 2007 Feb; 28(2):279-86. PubMed ID: 17241532
[TBL] [Abstract][Full Text] [Related]
55. Acute dyskinesias after metoclopramide withdrawal.
Modrego Pardo P; Perez Trullen JM
J Am Geriatr Soc; 1997 Apr; 45(4):536. PubMed ID: 9100735
[No Abstract] [Full Text] [Related]
56. Pharmacokinetic parameters of bromperidol in Korean subjects.
Lee SY; Kim YG; Kim HG; Kim JW
Hum Psychopharmacol; 2006 Aug; 21(6):409-12. PubMed ID: 16915578
[TBL] [Abstract][Full Text] [Related]
57. Genetic polymorphisms of metabolic enzymes CYP1A1, CYP2D6, GSTM1 and GSTT1 and leukemia susceptibility.
Chen HC; Hu WX; Liu QX; Li WK; Chen FZ; Rao ZZ; Liu XF; Luo YP; Cao YF
Eur J Cancer Prev; 2008 Jun; 17(3):251-8. PubMed ID: 18414197
[TBL] [Abstract][Full Text] [Related]
58. [Severe parkinsonism due to metoclopramide in a patient with polypharmacy].
Hoogendam A; Hofmeijer J; Frijns CJ; Heeringa M; Schouten-Tjin a Tsoi SL; Jansen PA
Ned Tijdschr Geneeskd; 2002 Jan; 146(4):175-7. PubMed ID: 11845569
[TBL] [Abstract][Full Text] [Related]
59. CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine.
Aklillu E; Kalow W; Endrenyi L; Harper P; Miura J; Ozdemir V
Pharmacogenet Genomics; 2007 Nov; 17(11):989-93. PubMed ID: 18075468
[TBL] [Abstract][Full Text] [Related]
60. Effects of CYP2D6 genetic polymorphism on the pharmacokinetics of metoclopramide.
Bae JW; Oh KY; Yoon SJ; Shin HB; Jung EH; Cho CK; Lim CW; Kang P; Choi CI; Jang CG; Lee SY; Lee YJ
Arch Pharm Res; 2020 Nov; 43(11):1207-1213. PubMed ID: 33247397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
